OBJECTIVE: To determine the effect of rimonabant on energy expenditure (O2 consumption) in rats at different metabolic states and in cannabinoid CB1 receptor-deficient (CB1R-/-) mice. DESIGN: Animals were exposed to light-dark cycles and fed only during dark cycles. Rimonabant or vehicle was administered together with food (absorptive), following overnight feeding (postabsorptive) or following a whole day of no food (fasting). Indirect calorimetric measurements, physical activity and food intake were measured continuously. RESULTS: Compared with vehicle-treated rats, rats administered 3 and 10 mg kg(-1) rimonabant showed an 18 and 49% increase in O2 consumption, respectively after 3 h. A second dose of rimonabant administered 9-14.5 h after the first one failed to affect O2 consumption, suggesting the development of tolerance. Similarly, stereotypic behaviors and ambulatory activity increased following the first dose but these effects were not observed after the second dose. Respiratory quotients revealed no effect of rimonabant on rates of carbohydrate and fat oxidation. Analysis of the correlation between O2 consumption and physical activity indicated that factors other than increased physical activity may contribute to the increase in O2 consumption. Similar studies in mice demonstrated that wild type but not CB1R-/- mice showed a change in O2 consumption and physical activity following rimonabant administration, suggesting that these effects are mediated by the cannabinoid CB1 receptor. CONCLUSION: Previous studies suggested that reduced food intake alone may not explain the weight reduction observed with rimonabant. Our studies suggest that rimonabant stimulates significant acute energy expenditure in non-obese rodents, which could not be completely accounted for by an increase in physical activity. However, with the observation that there is rapid development of tolerance, these results suggest that there may be additional mechanism(s) that lead to weight loss in these rodents.
OBJECTIVE: To determine the effect of rimonabant on energy expenditure (O2 consumption) in rats at different metabolic states and in cannabinoid CB1 receptor-deficient (CB1R-/-) mice. DESIGN: Animals were exposed to light-dark cycles and fed only during dark cycles. Rimonabant or vehicle was administered together with food (absorptive), following overnight feeding (postabsorptive) or following a whole day of no food (fasting). Indirect calorimetric measurements, physical activity and food intake were measured continuously. RESULTS: Compared with vehicle-treated rats, rats administered 3 and 10 mg kg(-1) rimonabant showed an 18 and 49% increase in O2 consumption, respectively after 3 h. A second dose of rimonabant administered 9-14.5 h after the first one failed to affect O2 consumption, suggesting the development of tolerance. Similarly, stereotypic behaviors and ambulatory activity increased following the first dose but these effects were not observed after the second dose. Respiratory quotients revealed no effect of rimonabant on rates of carbohydrate and fat oxidation. Analysis of the correlation between O2 consumption and physical activity indicated that factors other than increased physical activity may contribute to the increase in O2 consumption. Similar studies in mice demonstrated that wild type but not CB1R-/- mice showed a change in O2 consumption and physical activity following rimonabant administration, suggesting that these effects are mediated by the cannabinoid CB1 receptor. CONCLUSION: Previous studies suggested that reduced food intake alone may not explain the weight reduction observed with rimonabant. Our studies suggest that rimonabant stimulates significant acute energy expenditure in non-obese rodents, which could not be completely accounted for by an increase in physical activity. However, with the observation that there is rapid development of tolerance, these results suggest that there may be additional mechanism(s) that lead to weight loss in these rodents.
Authors: Nina L Cluny; Adam P Chambers; V Kiran Vemuri; Jodianne T Wood; Lindsay K Eller; Carmelina Freni; Raylene A Reimer; Alexandros Makriyannis; Keith A Sharkey Journal: Pharmacol Biochem Behav Date: 2010-11-04 Impact factor: 3.533
Authors: Malliga R Iyer; Resat Cinar; Jie Liu; Grzegorz Godlewski; Gergö Szanda; Henry Puhl; Stephen R Ikeda; Jeffrey Deschamps; Yong-Sok Lee; Peter J Steinbach; George Kunos Journal: Mol Pharmacol Date: 2015-05-26 Impact factor: 4.436
Authors: Whitney H Brown; Matthew P Gillum; Hui-Young Lee; Joao Paulo G Camporez; Xian-man Zhang; Jin Kwon Jeong; Tiago C Alves; Derek M Erion; Blas A Guigni; Mario Kahn; Varman T Samuel; Benjamin F Cravatt; Sabrina Diano; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2012-08-21 Impact factor: 11.205
Authors: Joyce M Richey; Orison O Woolcott; Darko Stefanovski; L Nicole Harrison; Dan Zheng; Maya Lottati; Isabel R Hsu; Stella P Kim; Morvarid Kabir; Karyn J Catalano; Jenny D Chiu; Viorica Ionut; Cathryn Kolka; Vahe Mooradian; Richard N Bergman Journal: Am J Physiol Endocrinol Metab Date: 2009-04-14 Impact factor: 4.310
Authors: Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer Journal: Trends Pharmacol Sci Date: 2015-03-18 Impact factor: 14.819